Edition:
India

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

4.58USD
12:51am IST
Change (% chg)

$-0.13 (-2.76%)
Prev Close
$4.71
Open
$4.74
Day's High
$4.87
Day's Low
$4.58
Volume
34,161
Avg. Vol
38,929
52-wk High
$7.03
52-wk Low
$1.82

Chart for

About

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $180.60
Shares Outstanding(Mil.): 34.14
Dividend: --
Yield (%): --

Financials

BRIEF-Agile Therapeutics Q3 loss per share $0.22

* Agile therapeutics reports third quarter 2017 financial results

07 Nov 2017

BRIEF-‍Caxton Corp reports 5.3 pct passive stake in Agile Therapeutics Inc

* ‍Caxton Corp reports 5.3 percent passive stake in Agile Therapeutics Inc as on August 9, 2017 - SEC filing​ Source text (http://bit.ly/2vKGGOo) Further company coverage:

19 Aug 2017

BRIEF-Agile Therapeutics announces proposed offering of common stock

* Agile Therapeutics announces proposed offering of common stock

03 Aug 2017

BRIEF-Agile Therapeutics reports second quarter 2017 financial results

* Q2 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S

28 Jul 2017

BRIEF-Agile Therapeutics announces FDA acceptance of NDA resubmission of Twirla

* Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla®

28 Jul 2017

BRIEF-Agile therapeutics resubmits new drug application for transdermal contraceptive patch

* Agile therapeutics resubmits new drug application (NDA) for its transdermal contraceptive patch, Twirla®

27 Jun 2017

Earnings vs. Estimates